Drug Profile
Tianeptine - Revive Therapeutics
Alternative Names: REV-001; REV-003Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Revive Therapeutics
- Developer Leiden University; Revive Therapeutics
- Class Anxiolytics; Nootropics; Small molecules; Thiazepines; Tricyclic antidepressants
- Mechanism of Action Serotonin uptake stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Respiratory insufficiency; Rett syndrome
Most Recent Events
- 28 Sep 2021 Discontinued - Phase-II for Respiratory insufficiency (Prevention) in Netherlands (PO) (Revive Therapeutics pipeline, September 2021)
- 28 Sep 2021 Discontinued - Preclinical for Rett syndrome in Canada (unspecified route) (Revive Therapeutics pipeline, September 2021)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Rett syndrome in Canada